Long-term oxygen therapy

F. Ioli, A. Braghiroli, C. F. Donner

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Controlled studies have demonstrated that the correction of tissue hypoxia increases survival and reduces pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) receiving oxygen therapy 15 h/day or longer. Long-term oxygen therapy (LTOT) is recommended to any patient with COPD who has a PaO2 of ≤ 7.3 kPa. In most countries, the PaO2 threshold is 8kPa in patients with chronic hypoxemia (PaO2≥55 mm Hg) with associated hematocrit ≥55%, pulmonary hypertension or cor pulmonale. Desaturations during sleep or exercise should be investigated, although a consensus as to whether and how these episodes should be treated has yet to be reached. The indications for LTOT in restrictive lung diseases, such as interstitial pulmonary fibrosis and pneumoconiosis, remain controversial. In many countries, oxygen is not prescribed if the patient is a current smoker. Breathlessness without hypoxemia should not be considered an indication for LTOT. The oxygen is usually administered through nasal cannula. Venturi type masks, nasopharyngeal and transtracheal catheters are associated with several drawbacks. Oxygen is usually supplied by the relatively cheap oxygen concentrator. Liquid oxygen is favored when a portable source is an important requirement. Many questions remain unanswered concerning the duration of added survival, the effect of LTOT on physiological parameters such as pulmonary artery pressure, respiratory failure in non-COPD patients, exercise and nocturnal desaturations.

Original languageEnglish
Pages (from-to)9-12
Number of pages4
JournalMonaldi Archives for Chest Disease - Cardiac Series
Volume49
Issue number3 SUPPL. 1
Publication statusPublished - 1994

Fingerprint

Oxygen
Therapeutics
Pulmonary Hypertension
Chronic Obstructive Pulmonary Disease
Exercise
Obstructive Lung Diseases
Pneumoconiosis
Pulmonary Heart Disease
Survival
Pulmonary Fibrosis
Masks
Hematocrit
Respiratory Insufficiency
Dyspnea
Pulmonary Artery
Lung Diseases
Consensus
Sleep
Catheters
Pressure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine

Cite this

Long-term oxygen therapy. / Ioli, F.; Braghiroli, A.; Donner, C. F.

In: Monaldi Archives for Chest Disease - Cardiac Series, Vol. 49, No. 3 SUPPL. 1, 1994, p. 9-12.

Research output: Contribution to journalArticle

Ioli, F, Braghiroli, A & Donner, CF 1994, 'Long-term oxygen therapy', Monaldi Archives for Chest Disease - Cardiac Series, vol. 49, no. 3 SUPPL. 1, pp. 9-12.
Ioli, F. ; Braghiroli, A. ; Donner, C. F. / Long-term oxygen therapy. In: Monaldi Archives for Chest Disease - Cardiac Series. 1994 ; Vol. 49, No. 3 SUPPL. 1. pp. 9-12.
@article{eec120c8d5c14b45a765226b18eee254,
title = "Long-term oxygen therapy",
abstract = "Controlled studies have demonstrated that the correction of tissue hypoxia increases survival and reduces pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) receiving oxygen therapy 15 h/day or longer. Long-term oxygen therapy (LTOT) is recommended to any patient with COPD who has a PaO2 of ≤ 7.3 kPa. In most countries, the PaO2 threshold is 8kPa in patients with chronic hypoxemia (PaO2≥55 mm Hg) with associated hematocrit ≥55{\%}, pulmonary hypertension or cor pulmonale. Desaturations during sleep or exercise should be investigated, although a consensus as to whether and how these episodes should be treated has yet to be reached. The indications for LTOT in restrictive lung diseases, such as interstitial pulmonary fibrosis and pneumoconiosis, remain controversial. In many countries, oxygen is not prescribed if the patient is a current smoker. Breathlessness without hypoxemia should not be considered an indication for LTOT. The oxygen is usually administered through nasal cannula. Venturi type masks, nasopharyngeal and transtracheal catheters are associated with several drawbacks. Oxygen is usually supplied by the relatively cheap oxygen concentrator. Liquid oxygen is favored when a portable source is an important requirement. Many questions remain unanswered concerning the duration of added survival, the effect of LTOT on physiological parameters such as pulmonary artery pressure, respiratory failure in non-COPD patients, exercise and nocturnal desaturations.",
author = "F. Ioli and A. Braghiroli and Donner, {C. F.}",
year = "1994",
language = "English",
volume = "49",
pages = "9--12",
journal = "Monaldi Archives for Chest Disease",
issn = "1122-0643",
publisher = "Fondazione Salvatore Maugeri",
number = "3 SUPPL. 1",

}

TY - JOUR

T1 - Long-term oxygen therapy

AU - Ioli, F.

AU - Braghiroli, A.

AU - Donner, C. F.

PY - 1994

Y1 - 1994

N2 - Controlled studies have demonstrated that the correction of tissue hypoxia increases survival and reduces pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) receiving oxygen therapy 15 h/day or longer. Long-term oxygen therapy (LTOT) is recommended to any patient with COPD who has a PaO2 of ≤ 7.3 kPa. In most countries, the PaO2 threshold is 8kPa in patients with chronic hypoxemia (PaO2≥55 mm Hg) with associated hematocrit ≥55%, pulmonary hypertension or cor pulmonale. Desaturations during sleep or exercise should be investigated, although a consensus as to whether and how these episodes should be treated has yet to be reached. The indications for LTOT in restrictive lung diseases, such as interstitial pulmonary fibrosis and pneumoconiosis, remain controversial. In many countries, oxygen is not prescribed if the patient is a current smoker. Breathlessness without hypoxemia should not be considered an indication for LTOT. The oxygen is usually administered through nasal cannula. Venturi type masks, nasopharyngeal and transtracheal catheters are associated with several drawbacks. Oxygen is usually supplied by the relatively cheap oxygen concentrator. Liquid oxygen is favored when a portable source is an important requirement. Many questions remain unanswered concerning the duration of added survival, the effect of LTOT on physiological parameters such as pulmonary artery pressure, respiratory failure in non-COPD patients, exercise and nocturnal desaturations.

AB - Controlled studies have demonstrated that the correction of tissue hypoxia increases survival and reduces pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) receiving oxygen therapy 15 h/day or longer. Long-term oxygen therapy (LTOT) is recommended to any patient with COPD who has a PaO2 of ≤ 7.3 kPa. In most countries, the PaO2 threshold is 8kPa in patients with chronic hypoxemia (PaO2≥55 mm Hg) with associated hematocrit ≥55%, pulmonary hypertension or cor pulmonale. Desaturations during sleep or exercise should be investigated, although a consensus as to whether and how these episodes should be treated has yet to be reached. The indications for LTOT in restrictive lung diseases, such as interstitial pulmonary fibrosis and pneumoconiosis, remain controversial. In many countries, oxygen is not prescribed if the patient is a current smoker. Breathlessness without hypoxemia should not be considered an indication for LTOT. The oxygen is usually administered through nasal cannula. Venturi type masks, nasopharyngeal and transtracheal catheters are associated with several drawbacks. Oxygen is usually supplied by the relatively cheap oxygen concentrator. Liquid oxygen is favored when a portable source is an important requirement. Many questions remain unanswered concerning the duration of added survival, the effect of LTOT on physiological parameters such as pulmonary artery pressure, respiratory failure in non-COPD patients, exercise and nocturnal desaturations.

UR - http://www.scopus.com/inward/record.url?scp=0028142849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028142849&partnerID=8YFLogxK

M3 - Article

VL - 49

SP - 9

EP - 12

JO - Monaldi Archives for Chest Disease

JF - Monaldi Archives for Chest Disease

SN - 1122-0643

IS - 3 SUPPL. 1

ER -